These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31535405)

  • 21. Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis.
    Kawamoto A; Fujii T; Mitani R; Suzuki Y; Yauchi T; Okamoto R
    Inflamm Bowel Dis; 2022 Aug; 28(8):1298-1299. PubMed ID: 35700275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A
    Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J; Kaasen Jørgensen K
    Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
    Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
    Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease.
    Elosua González A; Sanz Segura P; Oyón Lara D; López García S; Arroyo Villarino MT; Alcalá Escriche MJ; Ollero Domenche L; Rodríguez Gutiérrez C; Nantes Castillejo Ó
    Med Clin (Barc); 2020 Jun; 154(12):475-480. PubMed ID: 31785803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L; Iglesias Flores E; Benítez JM; Medina Medina R; Salgueiro Rodríguez I; Aguilar Melero P; Cárdenas Aranzana MJ; González Fernández R; Manzanares Martin B; García-Sánchez V
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.
    Dipasquale V; Pellegrino S; Ventimiglia M; Cucinotta U; Citrano M; Graziano F; Cappello M; Busacca A; Orlando A; Accomando S; Romano C;
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1007-1014. PubMed ID: 35830365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilars in paediatric inflammatory bowel disease.
    Sieczkowska-Golub J; Jarzebicka D; Oracz G; Kierkus J
    World J Gastroenterol; 2018 Sep; 24(35):4021-4027. PubMed ID: 30254406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation.
    Guiotto C; Italia A; Lavagna A; Rigazio C; Cosimato M; Ercole E; Mendolaro M; Rocca R; Daperno M
    Dig Liver Dis; 2019 Aug; 51(8):1117-1122. PubMed ID: 31272935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME; Vulto A; de Ridder L
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The switch to biosimilar infliximab as a cause of treatment cessation in 3 paediatric patients with Crohn's disease.
    Vande Velde S
    Acta Gastroenterol Belg; 2020; 83(4):657-659. PubMed ID: 33321025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
    Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.